Sansure Biotech Inc. (688289.SS)
CNY 19.21
(0.26%)
CNY 19.21
(0.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 427.46 Million CNY | -100.77% |
| 2022 | 2.33 Billion CNY | -10.76% |
| 2021 | 2.62 Billion CNY | -15.04% |
| 2020 | 3.08 Billion CNY | 6394.66% |
| 2019 | 47.51 Million CNY | 306.0% |
| 2018 | 11.7 Million CNY | 142.21% |
| 2017 | -27.73 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 83.7 Million CNY | 281.45% |
| 2024 Q2 | 19.53 Million CNY | -76.66% |
| 2024 Q3 | 34.23 Million CNY | 75.2% |
| 2023 Q2 | 39.52 Million CNY | -44.99% |
| 2023 FY | -18.02 Million CNY | -100.77% |
| 2023 Q1 | 71.85 Million CNY | -83.97% |
| 2023 Q3 | 254.95 Million CNY | 545.04% |
| 2023 Q4 | 21.94 Million CNY | -91.39% |
| 2022 Q4 | 448.25 Million CNY | -19.82% |
| 2022 Q2 | 554.48 Million CNY | -28.73% |
| 2022 Q1 | 778.02 Million CNY | 40.62% |
| 2022 Q3 | 559.03 Million CNY | 0.82% |
| 2022 FY | 2.33 Billion CNY | -10.76% |
| 2021 Q1 | 732.99 Million CNY | 3.07% |
| 2021 Q2 | 587.3 Million CNY | -19.88% |
| 2021 FY | 2.62 Billion CNY | -15.04% |
| 2021 Q4 | 553.27 Million CNY | -26.05% |
| 2021 Q3 | 748.21 Million CNY | 27.4% |
| 2020 FY | 3.08 Billion CNY | 6394.66% |
| 2020 Q4 | 711.15 Million CNY | -22.7% |
| 2020 Q1 | 228.79 Million CNY | 852.64% |
| 2020 Q2 | 1.22 Billion CNY | 435.86% |
| 2020 Q3 | 920.05 Million CNY | -24.96% |
| 2019 FY | 47.51 Million CNY | 306.0% |
| 2019 Q3 | 11.23 Million CNY | -7.21% |
| 2019 Q2 | 12.11 Million CNY | 8142.0% |
| 2019 Q1 | 146.96 Thousand CNY | 0.0% |
| 2019 Q4 | 24.01 Million CNY | 113.68% |
| 2018 FY | 11.7 Million CNY | 142.21% |
| 2017 FY | -27.73 Million CNY | 0.0% |